CapitolRadar tracks every publicly disclosed AORT trade by US congress members and corporate insiders: 5 disclosed trades (4 buys, 1 sells) by 2 tracked traders, from 2023-06-13 to 2026-08-20. Updated daily from official filings.
Want a ping when Congress buys AORT? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Artivion, Inc. (AORT) — Healthcare · Medical - Devices, market cap about $1.1B.
CapitolRadar analysis
4 buys lead 5 disclosed AORT trades
AORT, Artivion, Inc., has 5 tracked trades from 2023-06-13 through 2026-08-20: 4 buys and 1 sell involving 2 distinct traders. The activity is therefore buy-heavy by transaction count, although the sample is too small to establish a broad trading pattern. The available facts do not attribute the single sell to a named trader or provide transaction amounts, so buy and sell values cannot be compared.
The quarterly record is concentrated in two periods. 2026 Q3 accounts for 3 trades, all buys. 2023 Q3 contains 1 trade, also a buy, while 2023 Q2 contains 1 trade and no buys, corresponding to the lone sell in the five-trade history. No tracked activity is listed for the intervening quarters.
3 of 4 buys came from Gilbert Cisneros
Gilbert Cisneros made 3 AORT buys, with the latest dated 2026-08-20. Josh Gottheimer made 1 buy, most recently on 2023-07-14. Together, those records account for all 4 disclosed purchases. With only 2 distinct traders and 5 total transactions, conclusions about consistency, timing, or wider interest should remain limited.
2 buyers overlap in AMD, CRWD, GS and MSFT
Both tracked AORT buyers also bought AMD, CRWD, GS and MSFT. One of the two also bought BCRX, and one also bought FERG. These overlaps describe disclosed buying activity only; they do not establish a reason for the AORT trades or a relationship among the companies.
Disclosure timing and valuation are important caveats. Congressional transaction reports can appear up to 45 days after a trade, so disclosure dates may lag the underlying activity. Reported transaction amounts, when presented as ranges, are estimates rather than exact values. Here, no amount ranges were provided, and the five-trade sample is small.
Analysis written from the tracked record on 2026-09-12; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 3 | 3 | 0 |
| 2023 Q3 | 1 | 1 | 0 |
| 2023 Q2 | 1 | 0 | 1 |
Who is buying AORT?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Gilbert Cisneros | 3 | 2026-08-20 | — |
| Josh Gottheimer | 1 | 2023-07-14 | — |
Disclosed trades in AORT
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2026-07-16 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2026-07-15 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2023-07-14 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2023-06-13 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
CapitolRadar signal history
NEW PICK 2026-09-11
Rep. Gilbert Cisneros disclosed a $1,001–$15,000 purchase of Artivion stock. The panel passed mainly because he has no verified trading record against SPY, leaving the purchase signal unproven; no other tracked buyers added support. A verified history of similar purchases outperforming SPY would have been the strongest evidence to change the verdict, though the future-dated trade also needs confirmation.
NEW PICK 2026-09-09
Rep. Gilbert Ray Cisneros disclosed buying $1,001–$15,000 of AORT stock. The panel passed mainly because he has no verified trading history versus SPY, so this purchase is an unproven signal; no other tracked buyers added support. A verified record of similar purchases outperforming SPY would have been the clearest evidence to change the verdict.
These buyers also bought
Other stocks the tracked buyers of AORT disclosed buying in the last six months: CRWD (2) · MSFT (2) · AMD (2) · SAIL (2) · APH (1) · CSWI (1).
About Artivion, Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra desig…
Frequently asked questions
Which politicians bought AORT most?
Gilbert Cisneros leads with 3 disclosed buys, followed by Josh Gottheimer.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.